

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

1.     **(Currently Amended)**     A composition formulated for intramuscular injection comprising  
  
          a testosterone ester selected from the group of esters consisting of linear and branched noncanoates, decanoates, undecanoates, dodecanoates, tridecanoates, tetradecanoates, and pentadecanoates; and  
  
          a vehicle comprising castor oil in a concentration of 25 to ~~45%~~ 40% by volume and a co-solvent.
2.     **(Canceled)**
3.     **(Previously presented)**     The composition according to claim 1, wherein the testosterone ester is testosterone undecanoate.
4.     **(Canceled)**
5.     **(Original)**     The composition according to claim 1, wherein the vehicle comprises said castor oil and co-solvent in a volume ratio ranging between 1:0.2 to 1:3.

**6. (Original)** The composition according to claim 1, wherein the co-solvent is benzyl benzoate.

**7. – 21. (Canceled)**

**22. (Previously presented)** The composition according to claim 1, wherein the vehicle comprises the castor oil in a concentration of 25 to 30 vol%.

**23. (Original)** The composition according to claim 1, wherein the vehicle comprises said castor oil and co-solvent in a volume ratio ranging between 1:0.5 to 1:3.

**24. (Original)** The composition according to claim 1, wherein the vehicle comprises said castor oil and co-solvent in a volume ratio ranging between 1:0.75 to 1:2.5.

**25. (Original)** The composition according to claim 1, wherein the vehicle comprises said castor oil and co-solvent in a volume ratio ranging between 1:1 to 1:2.

**26. – 29. (Canceled)**

**30. (Previously presented)** The composition according to claim 3, wherein the testosterone undecanoate is provided in the composition in a dose of 150 to 500 mg/ml.

**31. (Canceled)**

**32. (Previously presented)** The composition according to claim 1, wherein the cosolvent is in an amount of 55 to 65 vol% in the composition.

**33. (Previously presented)** The composition according to claim 3, wherein the cosolvent is in an amount of 55 to 65 vol% in the composition.

**34. (Canceled)**

**35. (Previously presented)** The composition according to claim 3, wherein the cosolvent is benzyl benzoate.

**36. (Previously presented)** The composition according to claim 30, wherein the cosolvent is benzyl benzoate.

**37. (Previously presented)** The composition according to claim 1 in a form for single injection which contains 1000 mg of testosterone undecanoate in a vehicle containing 4 ml of a mixture of castor oil and benzyl benzoate in a ratio of 1:1.7 by volume

**38. (Withdrawn)** A method for male contraception in a man comprising administering to the man by intramuscular injection, an effective amount of a composition according to claim 1.

**39. (Withdrawn)** A method for treating primary or secondary hypogonadism in a man comprising administering to the man by intramuscular injection, an effective amount of a composition according to claim 1.

**40. (Withdrawn)** The method of claim 39, wherein primary hypogonadism is treated and said primary hypogonadism is derived from: testicular failure selected from the group consisting of cryptorchidism, bilateral testicular torsion, orchitis, orchidectomy, Klinefelter syndrome, chemotherapy and toxic damage from alcohol or heavy metals.

**41. (Withdrawn)** The method of claim 39, wherein secondary hypogonadism is treated and said secondary hypogonadism is derived from idiopathic gonadotropin releasing hormone (GnRH) deficiency or pituitary-hypothalamic injury caused by tumours, trauma or radiation.

**42. (Withdrawn)** A method for treating a disease or symptom associated with a deficient level of testosterone in a man who is in therapy with a progestin or a gonadotropin suppressive agent, comprising administering to the man by intramuscular injection, an effective amount of a composition according to claim 1.

**43. (Withdrawn)** The method of claim 41, wherein said deficient level of testosterone is such that the concentration of testosterone in serum of the man is less than 10 nmol/l.

**44. (Withdrawn)** The method of claim 38, wherein the testosterone ester is testosterone undecanoate.

**45. (Withdrawn)** The method of claim 39, wherein the testosterone ester is testosterone undecanoate.

**46. (Withdrawn)** The method of claim 42, wherein the testosterone ester is testosterone undecanoate.

**47. (Withdrawn)** The method of claim 38, wherein the composition is administered to provide the testosterone ester in a 6-week dose of 500 mg to 2000 mg, a 9-week dose of 500 mg to 2000 mg, a 10-week dose of 500 mg to 2000 mg, an 11-week dose of 500 mg to 2000 mg, a 12-week dose of 500 mg to 2000 mg, a 13-week dose of 500 mg to 2000 mg, a 14-week dose of 500 to 2000 mg, a 15-week dose of 500 to 2000 mg or a 16-week dose of 500 mg to 2000 mg.

**48. (Withdrawn)** The method of claim 39, wherein the composition is administered to provide the testosterone ester in a 6-week dose of 500 mg to 2000 mg, a 9-week dose of 500 mg to 2000 mg, a 10-week dose of 500 mg to 2000 mg, an 11-week dose of 500 mg to 2000 mg, a 12-week dose of 500 mg to 2000 mg, a 13-week dose of 500 mg to 2000 mg, a 14-week dose of 500 to 2000 mg, a 15-week dose of 500 to 2000 mg or a 16-week dose of 500 mg to 2000 mg.

**49. (Withdrawn)** The method of claim 42, wherein the composition is administered to

provide the testosterone ester in a 6-week dose of 500 mg to 2000 mg, a 9-week dose of 500 mg to 2000 mg, a 10-week dose of 500 mg to 2000 mg, an 11-week dose of 500 mg to 2000 mg, a 12-week dose of 500 mg to 2000 mg, a 13-week dose of 500 mg to 2000 mg, a 14-week dose of 500 to 2000 mg, a 15-week dose of 500 to 2000 mg or a 16-week dose of 500 mg to 2000 mg.

**50. (Withdrawn)** The method of claim 47, wherein said 6-, 9-, 10-, 11-, 12-, 13-, 14-, 15- or 16-week dose is of 750 mg to 1500 mg of the testosterone ester.

**51. (Withdrawn)** The method of claim 48, wherein said 6-, 9-, 10-, 11-, 12-, 13-, 14-, 15- or 16-week dose is of 750 mg to 1500 mg of the testosterone ester.

**52. (Withdrawn)** The method of claim 49, wherein said 6-, 9-, 10-, 11-, 12-, 13-, 14-, 15- or 16-week dose is of 750 mg to 1500 mg of the testosterone ester.

**53. (Withdrawn)** The method of claim 38, wherein the co-solvent is benzyl benzoate.

**54. (Withdrawn)** The method of claim 39, wherein the co-solvent is benzyl benzoate.

**55. (Withdrawn)** The method of claim 42, wherein the co-solvent is benzyl benzoate.

**56. (Previously presented)** The composition of claim 1, wherein the composition contains no plant oil other than castor oil.